Compass Therapeutics
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms (NCT07684170) | Compass Therapeutics | 2026-09-01 |
| A Phase 1 Study of the Safety and Tolerability of CTX-10726 (NCT07419841) | Compass Therapeutics | 2026-05-28 |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies (NCT06150664) | Compass Therapeutics | 2024-03-19 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (NCT05506943) | Compass Therapeutics | 2023-01-09 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
Track Compass Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.